Login to Your Account

Power of Predictive Modeling Helping to Speed MS Drug R&D

By Marie Powers
Staff Writer

Monday, November 11, 2013

Multiple sclerosis (MS) is a relentless disease, and one with a rising prevalence. The National Institutes of Health estimates that some 200 cases are diagnosed every week in the U.S. alone. The advent of oral therapies is a hopeful sign in the effort to slow progression of the disease. The approval of three MS drugs so far in 2013 – followed by a pipeline brimming with hundreds of compounds – speaks to the resources the biopharma industry is aiming at the disease. (See BioWorld Insight, Nov. 4, 2013.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription